Affinity Asset Advisors, LLC Nurix Therapeutics, Inc. Transaction History
Affinity Asset Advisors, LLC
- $596 Million
- Q2 2025
A detailed history of Affinity Asset Advisors, LLC transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Affinity Asset Advisors, LLC holds 967,620 shares of NRIX stock, worth $10 Million. This represents 1.85% of its overall portfolio holdings.
Number of Shares
967,620
Previous 810,669
19.36%
Holding current value
$10 Million
Previous $9.63 Million
14.44%
% of portfolio
1.85%
Previous 1.08%
Shares
11 transactions
Others Institutions Holding NRIX
# of Institutions
174Shares Held
79.3MCall Options Held
126KPut Options Held
11.3K-
Black Rock Inc. New York, NY6.82MShares$70.6 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT6.06MShares$62.8 Million2.45% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.47MShares$46.2 Million0.0% of portfolio
-
Commodore Capital LP New York, NY3.95MShares$40.9 Million4.19% of portfolio
-
Baker Bros. Advisors LP New York, NY3.88MShares$40.2 Million0.45% of portfolio
About Nurix Therapeutics, Inc.
- Ticker NRIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 47,147,800
- Market Cap $488M
- Description
- Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...